A mutation changes ligand selectivity and transmembrane signaling preference of the neurokinin-1 receptor

被引:19
|
作者
Riitano, D [1 ]
Werge, TM [1 ]
Costa, T [1 ]
机构
[1] IST SUPER SANITA,PHARMACOL LAB,I-00161 ROME,ITALY
关键词
D O I
10.1074/jbc.272.12.7646
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
studied the biochemical properties of a genetically engineered neurokinin-1 receptor (NK(1)R) in which two residues lying on the extracellular edge of the fourth transmembrane domain were replaced by equivalently located elements of the neurokinin-2 receptor (G166C, Y167F NK(1)R mutant), The mutation produced two effects, The first is enhancement of the apparent binding affinity for heterologous tachykinins (substance K and neurokinin B) and for N- or C-terminal modified analogues of substance P, but not for substance P itself, its full-length analogues, and several peptide and nonpeptide antagonists, Only two antagonists, as exceptions, were found 60 exhibit a diminished affinity for the mutant receptor. The second effect is a shift in NK(1)R preference for distinct G protein-mediated signaling pathways, NK(1)R mediated phosphoinositide hydrolysis was enhanced both in transiently and permanently transfected cells, while stimulation of cAMP accumulation did not change in transient expression experiments and was reduced in permanently expressing cells. The effect of the mutation on ligand affinity was not related to any obvious structural commonality, nor to the selectivity for different neurokinin receptors or the agonistic/antagonistic nature of the ligand, However, all ligands responding to the mutation appear to share the ability to induce phosphoinositide signaling more efficiently than cAMP responses when binding to NK(1)R. We suggest that the mutation shifts the internal equilibria of different functional forms of NK(1)R. A theoretical analysis according to a multistate allosteric model suggests that the link between binding and biological changes can result from altered stability constants of substates in the conformational space of the receptor.
引用
收藏
页码:7646 / 7655
页数:10
相关论文
共 50 条
  • [21] Signaling via neurokinin-1 receptor is required for cellular immunity induced by melanoma vaccines
    Larregina, Adriana
    Mathers, Alicia
    Tkacheva, Olga
    Morelli, Adrian
    JOURNAL OF IMMUNOLOGY, 2011, 186
  • [22] Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists
    Molinos-Quintana, A.
    Trujillo-Hacha, P.
    Piruat, J. I.
    Bejarano-Garcia, J. A.
    Garcia-Guerrero, E.
    Perez-Simon, J. A.
    Munoz, Miguel
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (01) : 17 - 26
  • [23] Regulation of neurokinin-1 receptor expression by GABAB receptor agonists
    Enna, SJ
    Harstad, EB
    McCarson, KE
    LIFE SCIENCES, 1998, 62 (17-18) : 1525 - 1530
  • [24] Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists
    A. Molinos-Quintana
    P. Trujillo-Hacha
    J. I. Piruat
    J. A. Bejarano-García
    E. García-Guerrero
    J. A. Pérez-Simón
    Miguel Muñoz
    Investigational New Drugs, 2019, 37 : 17 - 26
  • [25] A SELECTIVE AND EXTREMELY POTENT ANTAGONIST OF THE NEUROKININ-1 RECEPTOR
    SAKURADA, T
    MANOME, Y
    TANNO, K
    SAKURADA, S
    OHBA, M
    KISARA, K
    TERENIUS, L
    REGULATORY PEPTIDES, 1993, 46 (1-2) : 326 - 328
  • [26] Substance P and neurokinin-1 receptor modulation of HIV
    Ho, WZ
    Douglas, SD
    JOURNAL OF NEUROIMMUNOLOGY, 2004, 157 (1-2) : 48 - 55
  • [27] Substance P and the Neurokinin-1 Receptor: The New CRF
    Schank, Jesse R.
    Heilig, Markus
    ROLE OF NEUROPEPTIDES IN ADDICTION AND DISORDERS OF EXCESSIVE CONSUMPTION, 2017, 136 : 151 - 175
  • [28] The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors
    Kolorz, Julian
    Demir, Salih
    Gottschlich, Adrian
    Beirith, Iris
    Ilmer, Matthias
    Luethy, Daniel
    Walz, Christoph
    Dorostkar, Mario M.
    Magg, Thomas
    Hauck, Fabian
    von Schweinitz, Dietrich
    Kobold, Sebastian
    Kappler, Roland
    Berger, Michael
    CURRENT ONCOLOGY, 2022, 29 (01) : 94 - 110
  • [29] Neurokinin-1 receptor antagonists: a comprehensive patent survey
    Huang, Shih-Chung
    Korlipara, Vijaya L.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2010, 20 (08) : 1019 - 1045
  • [30] The neurokinin-1 receptor is crucial for the development of nonatopic asthma
    Van der Kleij, HP
    Kraneveld, AD
    Redegeld, FA
    Gerard, NP
    Morteau, O
    Nijkamp, FP
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (01) : S26 - S26